This is Part 3 of 5 in the “The Weight of Empire: Novo Nordisk’s Fight for Survival” series.
The price of a month’s supply of Wegovy had been $1,349. Then, on a November afternoon in Washington, a man who had never administered an injection, never read a clinical trial, and never visited a pharmaceutical manufacturing facility decided it should be $350. And so it was.
The announcement came from the Rose Garden, flanked by American flags and a lectern bearing the presidential seal. The President spoke for twelve minutes. He used the words “rip-off” three times and “American families” five times. He held up a chart showing the price of Wegovy in the United States versus Denmark, Germany, and Japan. The gap was obscene – Americans were paying four to eight times more for the same molecule – and the chart was designed to make that obscenity visual, visceral, impossible to explain away.
“Starting today,” the President said, leaning into the microphone with the showman’s instinct that had defined his political career, “the era of pharmaceutical companies treating American patients like ATMs is over.”
The Most Favored Nation executive order was brutally simple in concept. The U.S. government would peg the price of selected drugs to the lowest price paid by any of a basket of reference countries. For Wegovy and Ozempic, that meant the American price would be capped at roughly what Danish patients paid – about $350 a month for Wegovy, with a new oral formulation starting at $149.
The pharmaceutical industry’s response was immediate and furious. Lobbyists descended on Capitol Hill. Lawyers began drafting constitutional challenges. Industry groups issued statements about the death of innovation. But the political calculus was simple enough that any first-year staffer could have explained it: Americans wanted cheaper drugs, and the President was giving them cheaper drugs, and no amount of lobbying was going to reverse a policy that polled at seventy-eight percent approval.
In Bagsvaerd, Doustdar received the news in a conference room where his strategy team had been working through lunch. Someone pulled up the Rose Garden livestream on a laptop. They watched in silence. When it was over, the chief financial officer opened a spreadsheet he had been maintaining for exactly this scenario – the contingency model they all hoped would never be needed.
“Walk me through it,” Doustdar said.
“If the price holds at three-fifty across all GLP-1 products, U.S. revenue drops roughly forty percent on a per-unit basis. Volume could increase with better access, but not enough to offset. Net impact on operating income: somewhere between two and three billion dollars annually.”
“And if we refuse? If we challenge it in court?”
“We lose access to Medicare and Medicaid patients. Which is roughly thirty percent of U.S. volume. And the legal challenge takes two to three years, during which the political environment only gets worse.”
Doustdar stared at the spreadsheet. The numbers were not opinions. They were not scenarios to be debated. They were the shape of the new world, and the new world was significantly smaller than the old one.
“We accept,” he said.
The pricing blow would have been enough to define any corporate crisis. For Novo Nordisk, it was the second front of a war that was about to open a third.
Three weeks before the Washington announcement, on an October morning that began with drizzle and ended in institutional chaos, Helge Lund sent an email to the Novo Nordisk Foundation. The email was addressed to Lars Rebien Sorensen. It was six sentences long. It announced his resignation as board chairman, effective immediately, and cited “irreconcilable differences regarding the governance direction of the company.”
Within forty-eight hours, six independent directors followed him out the door.
Seven board members. Gone. Not over months of quiet disagreement, not through the polite Danish tradition of serving out one’s term and declining renomination. Gone in a burst of coordinated departures that told the market exactly what the carefully worded resignation letters did not: the board had lost its war with the Foundation, and the independent directors had decided that staying was worse than leaving.
The dispute had been building for months, rooted in a disagreement so fundamental that no compromise was possible. Lund and the independent directors believed the board should function as an independent check on both management and the Foundation – setting strategy, approving major decisions, and representing the interests of all shareholders, not just the one that controlled 77% of the votes. The Foundation, under Sorensen’s leadership, believed something different. The Foundation believed it was the ultimate custodian of Novo Nordisk’s future, and that its voting power gave it the right – the obligation, even – to direct the company’s course.
These two views had coexisted for years, papered over by a stock price that kept climbing and a CEO who served as a buffer between the board and the Foundation. With Jorgensen gone and the stock in decline, the buffer disappeared, and the underlying conflict became impossible to ignore.
“Helge tried to have the conversation with Lars about boundaries,” one former director told the Financial Times, speaking on condition of anonymity. “Lars listened politely. And then Lars did exactly what Lars was always going to do.”
What Lars Rebien Sorensen did was assume the board chairmanship himself.
The announcement was made at an extraordinary shareholder meeting in November, called to approve the new board composition. The Foundation’s 77% voting power made the outcome certain. Minority shareholders – pension funds, sovereign wealth vehicles, retail investors who collectively owned more than seventy percent of the company’s economic value – could object, protest, and vote no. It would not matter. The Foundation’s shares carried the votes, and the votes carried the day.
Sorensen addressed the meeting from the stage of the Bella Center in Copenhagen, speaking without notes in the measured tone that generations of Novo Nordisk employees had learned to associate with authority itself.
“I understand the concerns that have been raised about my assuming this role while continuing to chair the Foundation,” he said. “I want to assure you that these roles are complementary, not conflicting. The Foundation’s interests and the company’s interests are aligned. They have always been aligned. And in this period of exceptional challenge, the company benefits from having a chairman who understands both the business and the institutional framework that supports it.”
The minority shareholders were not assured. In the question-and-answer session that followed, a representative from one of Europe’s largest pension funds stood and asked, in a voice that carried across the auditorium, a question that Sorensen had almost certainly anticipated but could not satisfactorily answer.
“Mr. Sorensen, you now chair the board that is supposed to oversee the company. You also chair the Foundation that controls 77% of the company’s votes. Who, exactly, oversees you?”
Sorensen paused. “The Foundation’s charter, its board of trustees, and Danish corporate law provide the necessary checks and balances.”
“With respect,” the pension fund representative said, “Danish corporate law is what got us into this situation.”
There was no applause. But there was a murmur – the sound of several hundred institutional investors recognizing that someone had said the thing they had all been thinking.
While the governance crisis played out in boardrooms and shareholder meetings, a different kind of war was being fought in federal courthouses across the United States.
Compounding pharmacies – small operations that custom-mix medications for individual patients – had been producing semaglutide, the active ingredient in Ozempic and Wegovy, since the FDA placed the drugs on its shortage list in 2023. The legal basis was straightforward: under federal law, compounding pharmacies could produce copies of drugs that were in shortage, as long as they used bulk pharmaceutical ingredients and followed FDA guidelines.
For Novo Nordisk, the compounding pharmacies represented an existential annoyance. They were selling semaglutide injections for as little as $200 a month – a fraction of the list price – and their customer base was growing rapidly. Telehealth companies advertised “compounded semaglutide” as a cheaper alternative. Social media influencers promoted it. Patients who couldn’t afford or couldn’t access the branded drugs turned to compounders with the enthusiasm of people who had found a loophole in a system designed to exclude them.
Novo Nordisk’s legal response was overwhelming. More than 130 lawsuits, filed in federal courts from Florida to California, alleging that compounding pharmacies were manufacturing an unapproved drug using substandard ingredients. The company’s lawyers argued that semaglutide could not be safely compounded, that the bulk ingredients used by compounders were not equivalent to Novo’s proprietary formulation, and that patients were being put at risk.
The compounders fought back. Their lawyers argued that Novo Nordisk was using the legal system to protect a monopoly, that the drugs they produced were safe and effective, and that the real danger was not compounded semaglutide but the original pricing that put the branded version out of reach for millions of Americans.
In a courtroom in Fort Worth, Texas, a lawyer for a compounding pharmacy chain delivered an argument that captured the irony of the entire situation. “Novo Nordisk is suing us,” he said, “for making their drug affordable. They call it protecting patients. I call it protecting profits.”
The judge did not rule on the merits that day. But the lawyer’s phrase – “protecting patients or protecting profits” – migrated from the courtroom to Twitter to the evening news within hours. It became the kind of soundbite that no corporate communications department could neutralize, because it contained just enough truth to be indestructible.
Through all of this – the price cuts, the board collapse, the litigation war – Novo Nordisk was also losing a different kind of battle, one fought not in courtrooms or press conferences but in the quiet corridors of biotech dealmaking.
Metsera, a small obesity-focused biotech company, had developed a next-generation GLP-1 compound that early data suggested could be a significant advance over existing drugs. For Novo Nordisk, acquiring Metsera would have meant securing a pipeline asset capable of competing with Eli Lilly’s next wave of obesity treatments. For the company’s R&D strategy – weakened by CagriSema’s disappointing results – Metsera was not just attractive. It was necessary.
The bidding process lasted three weeks. Novo Nordisk made an aggressive offer. Pfizer made a more aggressive one. When the deal closed in November, it was Pfizer’s name on the press release, and the acquisition price – reportedly in excess of $2 billion – reflected the desperation of companies fighting for position in a market that everyone knew was going to be enormous but no one knew who would dominate.
For Doustdar, the Metsera loss was a different kind of wound than the pricing order or the board resignations. Those were external blows – forces acting on the company from outside. Metsera was a failure of internal capability. Novo Nordisk had not been outbid because it lacked money. It had been outbid because its declining stock price, its governance turmoil, and its strategic uncertainty had made it a less attractive partner than Pfizer. The biotech’s founders had looked at Novo Nordisk and seen a company in crisis. They had looked at Pfizer and seen stability.
That calculation – the market’s assessment of who was strong and who was wounded – was as damaging as any pricing order. In the pharmaceutical industry, the ability to acquire pipeline assets depends on being perceived as a winner. Losers attract neither talent nor deals.
On a rain-soaked evening in late November, in a private dining room at a restaurant in Mayfair, two fund managers sat across from each other over plates of Dover sole that neither was eating. Both held significant positions in Novo Nordisk. Both had watched those positions lose roughly half their value in less than a year.
The older of the two – a woman who ran the healthcare allocation for one of Europe’s largest sovereign wealth funds – had spent the afternoon in a meeting with Novo Nordisk’s investor relations team. The presentation had been professional, thorough, and entirely unconvincing. Doustdar’s team had walked through the restructuring plan, the pricing adjustment strategy, the pipeline outlook, and the governance changes with the confidence of people who had rehearsed their talking points until the words came out smooth and automatic.
“They kept saying the Foundation structure is an asset,” she told her colleague, setting down her fork. “That it provides stability, long-term thinking, insulation from market pressure.”
“And?”
“And I used to believe them. Five years ago, when the stock was going up and the Foundation was funding cancer research and everyone was writing case studies about how the Danish governance model was the future of responsible capitalism – I believed them.”
She picked up her wine glass, turned it slowly in her fingers, and set it down without drinking.
“I don’t believe them anymore. The Foundation structure was designed for a company that was winning. It was designed for a world where the biggest risk was short-term shareholder activism. But that’s not the world we’re in. The world we’re in has a U.S. president setting drug prices by executive order, a competitor that’s eating their lunch, and a board that just lost its entire independent wing because one man decided he should be chairman of everything.”
Her colleague leaned back. “So what are you saying?”
“I’m saying what the market has been thinking but nobody wants to say out loud. The Foundation’s control structure – the thing that was supposed to protect the company from short-term thinking – may be the very thing that is killing it.”
The rain streaked down the windows of the restaurant. In Copenhagen, it was past midnight. The Novo Nordisk campus was dark except for the security lights and the glow from one corner office on the executive floor, where someone – it was impossible to tell who from this distance – was still working.
This is a work of fiction. While inspired by real events and public information, all characters, dialogue, and internal deliberations are entirely imagined. Any resemblance to actual private conversations or decisions is coincidental.
